vs

Side-by-side financial comparison of BeOne Medicines Ltd. (ONC) and Rollins, Inc. (ROL). Click either name above to swap in a different company.

BeOne Medicines Ltd. is the larger business by last-quarter revenue ($1.5B vs $906.4M, roughly 1.7× Rollins, Inc.). Rollins, Inc. runs the higher net margin — 11.9% vs 4.4%, a 7.5% gap on every dollar of revenue. On growth, BeOne Medicines Ltd. posted the faster year-over-year revenue change (32.8% vs 10.2%). BeOne Medicines Ltd. produced more free cash flow last quarter ($379.8M vs $111.2M). Over the past eight quarters, BeOne Medicines Ltd.'s revenue compounded faster (41.2% CAGR vs 0.8%).

BeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment.

Rollins, Inc. is a North American pest control company serving residential and commercial clients. Operating globally through its wholly owned subsidiaries, Orkin, Inc., PCO Services, HomeTeam Pest Defense, Western Pest Services, Industrial Fumigant Company, TruTech, Critter Control, Crane, Waltham, OPC Services, PermaTreat, Northwest Exterminating, McCall Service and Clark Pest Control, as well UK subsidiaries Integrated Pest Management Limited, Safeguard Pest Control, NBC Environment, Europ...

ONC vs ROL — Head-to-Head

Bigger by revenue
ONC
ONC
1.7× larger
ONC
$1.5B
$906.4M
ROL
Growing faster (revenue YoY)
ONC
ONC
+22.6% gap
ONC
32.8%
10.2%
ROL
Higher net margin
ROL
ROL
7.5% more per $
ROL
11.9%
4.4%
ONC
More free cash flow
ONC
ONC
$268.6M more FCF
ONC
$379.8M
$111.2M
ROL
Faster 2-yr revenue CAGR
ONC
ONC
Annualised
ONC
41.2%
0.8%
ROL

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
ONC
ONC
ROL
ROL
Revenue
$1.5B
$906.4M
Net Profit
$66.5M
$107.8M
Gross Margin
90.5%
Operating Margin
12.4%
16.1%
Net Margin
4.4%
11.9%
Revenue YoY
32.8%
10.2%
Net Profit YoY
143.8%
2.5%
EPS (diluted)
$0.05
$0.22

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ONC
ONC
ROL
ROL
Q1 26
$906.4M
Q4 25
$1.5B
$912.9M
Q3 25
$1.4B
$1.0B
Q2 25
$1.3B
$999.5M
Q1 25
$1.1B
$822.5M
Q4 24
$1.1B
$832.2M
Q3 24
$1.0B
$916.3M
Q2 24
$929.2M
$891.9M
Net Profit
ONC
ONC
ROL
ROL
Q1 26
$107.8M
Q4 25
$66.5M
$116.4M
Q3 25
$124.8M
$163.5M
Q2 25
$94.3M
$141.5M
Q1 25
$1.3M
$105.2M
Q4 24
$-151.9M
$105.7M
Q3 24
$-121.3M
$136.9M
Q2 24
$-120.4M
$129.4M
Gross Margin
ONC
ONC
ROL
ROL
Q1 26
Q4 25
90.5%
Q3 25
86.1%
Q2 25
87.5%
Q1 25
85.2%
Q4 24
85.8%
Q3 24
83.0%
Q2 24
85.1%
Operating Margin
ONC
ONC
ROL
ROL
Q1 26
16.1%
Q4 25
12.4%
17.5%
Q3 25
11.5%
21.9%
Q2 25
6.7%
19.8%
Q1 25
1.0%
17.3%
Q4 24
-7.0%
18.1%
Q3 24
-12.0%
20.9%
Q2 24
-11.5%
20.4%
Net Margin
ONC
ONC
ROL
ROL
Q1 26
11.9%
Q4 25
4.4%
12.8%
Q3 25
8.8%
15.9%
Q2 25
7.2%
14.2%
Q1 25
0.1%
12.8%
Q4 24
-13.5%
12.7%
Q3 24
-12.1%
14.9%
Q2 24
-13.0%
14.5%
EPS (diluted)
ONC
ONC
ROL
ROL
Q1 26
$0.22
Q4 25
$0.05
$0.24
Q3 25
$0.08
$0.34
Q2 25
$0.06
$0.29
Q1 25
$0.00
$0.22
Q4 24
$-0.10
$0.22
Q3 24
$-0.09
$0.28
Q2 24
$-0.09
$0.27

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ONC
ONC
ROL
ROL
Cash + ST InvestmentsLiquidity on hand
$4.5B
$116.5M
Total DebtLower is stronger
$836.4M
$650.6M
Stockholders' EquityBook value
$4.4B
$1.4B
Total Assets
$8.2B
$3.2B
Debt / EquityLower = less leverage
0.19×
0.47×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ONC
ONC
ROL
ROL
Q1 26
$116.5M
Q4 25
$4.5B
$100.0M
Q3 25
$4.0B
$127.4M
Q2 25
$2.8B
$123.0M
Q1 25
$2.5B
$201.2M
Q4 24
$2.6B
$89.6M
Q3 24
$2.7B
$95.3M
Q2 24
$2.6B
$106.7M
Total Debt
ONC
ONC
ROL
ROL
Q1 26
$650.6M
Q4 25
$836.4M
$486.1M
Q3 25
$485.7M
Q2 25
$485.3M
Q1 25
$485.5M
Q4 24
$395.3M
Q3 24
Q2 24
Stockholders' Equity
ONC
ONC
ROL
ROL
Q1 26
$1.4B
Q4 25
$4.4B
$1.4B
Q3 25
$4.1B
$1.5B
Q2 25
$3.8B
$1.4B
Q1 25
$3.5B
$1.4B
Q4 24
$3.3B
$1.3B
Q3 24
$3.4B
$1.3B
Q2 24
$3.4B
$1.2B
Total Assets
ONC
ONC
ROL
ROL
Q1 26
$3.2B
Q4 25
$8.2B
$3.1B
Q3 25
$7.6B
$3.2B
Q2 25
$6.3B
$3.2B
Q1 25
$5.8B
$2.9B
Q4 24
$5.9B
$2.8B
Q3 24
$5.8B
$2.8B
Q2 24
$5.7B
$2.8B
Debt / Equity
ONC
ONC
ROL
ROL
Q1 26
0.47×
Q4 25
0.19×
0.35×
Q3 25
0.32×
Q2 25
0.34×
Q1 25
0.36×
Q4 24
0.30×
Q3 24
Q2 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ONC
ONC
ROL
ROL
Operating Cash FlowLast quarter
$417.3M
$118.4M
Free Cash FlowOCF − Capex
$379.8M
$111.2M
FCF MarginFCF / Revenue
25.4%
12.3%
Capex IntensityCapex / Revenue
2.5%
0.8%
Cash ConversionOCF / Net Profit
6.28×
1.10×
TTM Free Cash FlowTrailing 4 quarters
$941.7M
$621.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ONC
ONC
ROL
ROL
Q1 26
$118.4M
Q4 25
$417.3M
$164.7M
Q3 25
$402.6M
$191.3M
Q2 25
$263.6M
$175.1M
Q1 25
$44.1M
$146.9M
Q4 24
$75.2M
$188.2M
Q3 24
$188.4M
$146.9M
Q2 24
$-95.6M
$145.1M
Free Cash Flow
ONC
ONC
ROL
ROL
Q1 26
$111.2M
Q4 25
$379.8M
$159.0M
Q3 25
$354.5M
$182.8M
Q2 25
$219.8M
$168.0M
Q1 25
$-12.3M
$140.1M
Q4 24
$-17.3M
$184.0M
Q3 24
$54.7M
$139.4M
Q2 24
$-205.5M
$136.4M
FCF Margin
ONC
ONC
ROL
ROL
Q1 26
12.3%
Q4 25
25.4%
17.4%
Q3 25
25.1%
17.8%
Q2 25
16.7%
16.8%
Q1 25
-1.1%
17.0%
Q4 24
-1.5%
22.1%
Q3 24
5.5%
15.2%
Q2 24
-22.1%
15.3%
Capex Intensity
ONC
ONC
ROL
ROL
Q1 26
0.8%
Q4 25
2.5%
0.6%
Q3 25
3.4%
0.8%
Q2 25
3.3%
0.7%
Q1 25
5.0%
0.8%
Q4 24
8.2%
0.5%
Q3 24
13.3%
0.8%
Q2 24
11.8%
1.0%
Cash Conversion
ONC
ONC
ROL
ROL
Q1 26
1.10×
Q4 25
6.28×
1.41×
Q3 25
3.22×
1.17×
Q2 25
2.79×
1.24×
Q1 25
34.71×
1.40×
Q4 24
1.78×
Q3 24
1.07×
Q2 24
1.12×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons